Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") (Nasdaq: ARWR). Investors who purchased or otherwise acquired shares between May 11, 2015 and November 8, 2016 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the January 16, 2017 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The complaint alleges that during the Class Period, Arrowhead made false and misleading statements and/or failed to disclose: that its drug candidate ARC-520 was fatal at certain doses; that the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; that the Company overstated the approval prospects and commercial viability of ARC-520; and that as a result of the above, Arrowhead's public statements were materially false and misleading at all relevant times. On November 8, 2016, Arrowhead revealed that the U.S. Food & Drug Administration will be placing a clinical hold on its Heparc-2004 clinical study of ARC-520, likely due to deaths at the highest dose of an ongoing non-human primate toxicology study. When this news was announced, shares of Arrowhead fell in value, causing investors harm.